With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

2.

MRI can save rectal cancer patients from surgery, study suggests

3.

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

4.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

5.

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot